免疫失调疾病的靶向治疗。

IF 2.6 4区医学 Q2 RHEUMATOLOGY

Rheumatic Disease Clinics of North America Pub Date : 2023-08-23 DOI:10.1016/j.rdc.2023.07.002

Smriti Mohan MD

引用次数: 0

摘要

对自身炎症和自身免疫性疾病的分子知识不断增加，使这些疾病能够得到更有针对性的治疗。炎症性疾病的治疗通常针对白细胞介素-1（IL-1）阻断，并可能使用其他针对细胞因子如IL-18和IL-6的抑制剂。Janus激酶抑制可能会改善干扰素疾病和一些具有自身免疫和自身炎症重叠特征的疾病。自身免疫条件也可能对不同细胞因子的抑制以及T和B淋巴细胞的抑制作出反应。通过靶向/精准医学方法进行有效治疗的可能性越来越大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Targeted Treatment of Diseases of Immune Dysregulation

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Rheumatic Disease Clinics of North America 医学-风湿病学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Rheumatic Disease Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each issue (February, May, August, and November) focuses on a single topic in rheumatology and is presented under the direction of an experienced editor. Topics include osteoarthritis, rheumatoid arthritis, crystal diseases, MSK exam, disorders of the bone, immunodeficiency states, lupus, neuromuscular disease, pain disorders, scleroderma, vasculitis, pediatrics, therapeutics, treatment guidelines, and treatment modalities.